|
|
| Attention Investors |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
Your results on : Equity | Company Profile | Detailed Quotes |
|
|
|
|
|
|
|
|
|
|
|
| Stock Price Details |
|
Chart |
|
| Last Price |
895.20 |
|
| Change |
-1.10 (-0.12%) |
|
| Best Buy |
0(x0) |
|
| Best Sell |
0(x0) |
|
| Today's Range |
851.70
- 909.95 |
|
| 52-Week Range |
300.33
- 999.00 |
|
|
|
1 Day
| 5 Day
| 3 Month
| 1 Year
| 5 Year
|
|
|
|
| Index Details |
|
| BSE SmallCap |
|
| News |
|
Corporate Details |
|
|
|
| Incorporation Year : 1989 |
|
| Chairman : Mahavir Prasad Taparia |
|
| Ownership Group : Taparia |
|
| Sector : MAN |
|
| Industry : Petrochemicals |
|
| Registered Office |
|
Supreme Petrochem Ltd 167 Guru Hargovindji Marg, Andheri(East) Chakala 5th Flr, , Maharashtra-400093 |
|
Phone:91-022-67091900 Fax:91-022-40055681 |
|
| E-Mail : corporate@spl.co.in |
|
| URL : http://www.supremepetrochem.com |
|
|
|
| Investor Returns |
|
| |
|
Date |
|
Price (Rs) |
|
Returns (%) |
|
|
| 1Week |
17-Jul-2026 |
694.70 |
6.66 |
|
| 1Month |
24-Jun-2026 |
752.60 |
-1.54 |
|
| 3Month |
24-Apr-2026 |
813.40 |
-8.90 |
|
| 6Month |
27-Jan-2026 |
506.00 |
46.44 |
|
| 1Year |
24-Jul-2025 |
808.15 |
-8.31 |
|
|
|
|
| Mutual Funds Holding |
|
| No Data Found |
|
|
|
|
| Groups : Pharmaceuticals - Indian - Formulations |
|
| Company |
|
Last Price(Rs) |
|
Change(%) |
|
52Week High(Rs) |
|
52Week Low(Rs) |
|
Market Cap(Rs Cr.) |
| Torrent Pharmaceuticals Ltd |
4,959.80 |
-2.09 |
5,084.85 |
3,480.00 |
188,654.85 |
|
| Ajanta Pharma Ltd |
3,366.45 |
-2.16 |
3,598.40 |
2,335.00 |
42,058.95 |
|
| Gland Pharma Ltd |
2,378.35 |
0.03 |
2,574.00 |
1,575.00 |
39,233.19 |
|
| Rubicon Research Ltd |
1,519.10 |
-0.78 |
1,545.60 |
571.00 |
25,123.29 |
|
| ERIS Lifesciences Ltd |
1,398.90 |
0.27 |
1,887.65 |
1,237.90 |
19,385.75 |
|
|
|
|
|
|
|
| |
|
|
| |
| X |
| Filing complaints on SCORES |
| Easy & Quick |
| |
| › |
Register on SCORES Portal |
› |
Mandatory details for filing complaints on SCORES
| Name |
PAN |
Address |
Mobile No. |
Email ID |
|
| › |
Benefits: |
| |
|
|
|